These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 29800728)

  • 21. Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window.
    Sloane JL; Benner NL; Keenan KN; Zang X; Soliman MSA; Wu X; Dimapasoc M; Chun TW; Marsden MD; Zack JA; Wender PA
    Proc Natl Acad Sci U S A; 2020 May; 117(20):10688-10698. PubMed ID: 32371485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
    Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
    J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tracking HIV Rebound following Latency Reversal Using Barcoded HIV.
    Marsden MD; Zhang TH; Du Y; Dimapasoc M; Soliman MSA; Wu X; Kim JT; Shimizu A; Schrier A; Wender PA; Sun R; Zack JA
    Cell Rep Med; 2020 Dec; 1(9):100162. PubMed ID: 33377133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Production from Latently Infected Resting CD4
    Zerbato JM; Tachedjian G; Sluis-Cremer N
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal.
    Stoszko M; De Crignis E; Rokx C; Khalid MM; Lungu C; Palstra RJ; Kan TW; Boucher C; Verbon A; Dykhuizen EC; Mahmoudi T
    EBioMedicine; 2016 Jan; 3():108-121. PubMed ID: 26870822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency.
    de Armas LR; Gavegnano C; Pallikkuth S; Rinaldi S; Pan L; Battivelli E; Verdin E; Younis RT; Pahwa R; Williams SL; Schinazi RF; Pahwa S
    Front Immunol; 2021; 12():720697. PubMed ID: 34531866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Combinations of Protein Kinase C Activators and Histone Deacetylase Inhibitors That Potently Reactivate Latent HIV.
    Curreli F; Ahmed S; Victor SMB; Debnath AK
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32503121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
    Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thiostrepton Reactivates Latent HIV-1 through the p-TEFb and NF-κB Pathways Mediated by Heat Shock Response.
    Peng W; Hong Z; Chen X; Gao H; Dai Z; Zhao J; Liu W; Li D; Deng K
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylase inhibition reduces deleterious cytokine release induced by ingenol stimulation.
    Larragoite ET; Nell RA; Martins LJ; Barrows LR; Planelles V; Spivak AM
    Biochem Pharmacol; 2022 Jan; 195():114844. PubMed ID: 34801521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.
    Gupta V; Dixit NM
    PLoS Comput Biol; 2018 Feb; 14(2):e1006004. PubMed ID: 29451894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection.
    Garcia-Vidal E; Badia R; Pujantell M; Castellví M; Felip E; Clotet B; Riveira-Muñoz E; Ballana E; Esté JA
    Antiviral Res; 2019 Aug; 168():18-27. PubMed ID: 31077767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective BCL-X
    Ren Y; Huang SH; Macedo AB; Ward AR; Alberto WDC; Klevorn T; Leyre L; Copertino DC; Mota TM; Chan D; Truong R; Rohwetter T; Zumbo P; Dündar F; Betel D; Kovacs C; Benko E; Bosque A; Jones RB
    J Virol; 2021 Jul; 95(15):e0242520. PubMed ID: 33980597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. G-quadruplex ligands targeting telomeres do not inhibit HIV promoter activity and cooperate with latency reversing agents in killing latently infected cells.
    Piekna-Przybylska D; Bambara RA; Maggirwar SB; Dewhurst S
    Cell Cycle; 2020 Sep; 19(18):2298-2313. PubMed ID: 32807015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1.
    Martínez-Bonet M; Clemente MI; Serramía MJ; Muñoz E; Moreno S; Muñoz-Fernández MÁ
    Sci Rep; 2015 Nov; 5():16445. PubMed ID: 26563568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed.
    Rezaei SD; Lu HK; Chang JJ; Rhodes A; Lewin SR; Cameron PU
    J Virol; 2018 Jul; 92(13):. PubMed ID: 29643247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short Communication: Preferential Killing of HIV Latently Infected CD4(+) T Cells by MALT1 Inhibitor.
    Li H; He H; Gong L; Fu M; Wang TT
    AIDS Res Hum Retroviruses; 2016 Feb; 32(2):174-7. PubMed ID: 26728103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal.
    Martínez-Bonet M; Clemente MI; Álvarez S; Díaz L; García-Alonso D; Muñoz E; Moreno S; Muñoz-Fernández MÁ
    Antiviral Res; 2015 Nov; 123():163-71. PubMed ID: 26427554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells.
    López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Vivancos MJ; Luna L; Moreno S
    Biochem Pharmacol; 2020 Dec; 182():114231. PubMed ID: 32979351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T cell toxicity of HIV latency reversing agents.
    Zhao M; De Crignis E; Rokx C; Verbon A; van Gelder T; Mahmoudi T; Katsikis PD; Mueller YM
    Pharmacol Res; 2019 Jan; 139():524-534. PubMed ID: 30366100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.